Oruka Therapeutics to Present at Multiple March Investor Conferences
Oruka Therapeutics (Nasdaq: ORKA), a clinical stage biotechnology company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, has announced its participation in two major investor conferences in March 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oruka Therapeutics (Nasdaq: ORKA), a clinical stage biotechnology company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, has announced its participation in two major investor conferences in March 2025.
The company will present at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4th, 2025, at 10:30 AM ET, and at the Leerink Global Healthcare Conference on Wednesday, March 12th, 2025, at 8:40 AM ET.
Investors can access the webcasts and replays of these presentations through Oruka's investor events website at https://ir.orukatx.com/news-events/events-presentations.
Details
News Market Reaction – ORKA
The recorded move for ORKA in the trading session of this news was -2.18%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:
TD Cowen’s 45th Annual Health Care Conference
Date: Tuesday, March 4th, 2025
Time: 10:30AM ET
Leerink Global Healthcare Conference
Date: Wednesday, March 12th, 2025
Time: 8:40AM ET
A webcast and replay of Oruka’s presentation will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.